McElvany K D, Katzenellenbogen J A, Shafer K E, Siegel B A, Senderoff S G, Welch M J
J Nucl Med. 1982 May;23(5):425-30.
An estrogen-receptor-binding radiopharmaceutical, 16 alpha-[77Br]bromoestradiol-17 beta, has been used successfully at high specific activity to image carcinogen-induced mammary tumors in rats and in preliminary studies to image breast tumors in patients. The biodistribution of the labeled estrogen in rats and its clearance in a monkey were used to estimate the radiation absorbed doses to a human resulting from administration of the radiopharmaceutical. Preliminary imaging studies in patients with mammary carcinoma show promising results and warrant further development of radiolabeled estrogens, particularly those carrying positron emitters that could permit positron emission tomography--for example Br-75 or F-18.
一种雌激素受体结合放射性药物，16α-[77Br]溴雌二醇-17β，已成功用于高比活度成像大鼠致癌物诱导的乳腺肿瘤，并用于初步研究对患者乳腺肿瘤进行成像。标记雌激素在大鼠体内的生物分布及其在猴子体内的清除情况，被用于估算给予该放射性药物后人体所吸收的辐射剂量。对乳腺癌患者的初步成像研究显示出有前景的结果，这表明放射性标记雌激素，特别是那些携带可用于正电子发射断层扫描的正电子发射体（如Br-75或F-18）的雌激素，值得进一步研发。
